Apricus Biosciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: eico20 who wrote (1670)

2/9/2016 10:37:04 AM

From: eico20

Read Replies (1) of 2026

just heard from Mat beck, USA will be cold temp, and RTD is ongoing studies and transitioning to a new material, they must have had an issue, add to the fact, as Pascoe just stated in the CC, that they are trying to improve the cold temp device, it looks like RTD had an issue and is further away now, but how good will the new cold temp be, important questions

This refers to RTD.

§Transition to dispenser with a new material of construction underway
§Potential to enhance stability profile/shelf-life versus existing dispenser

Additional RTD studies are ongoing. Apricus' focus is on getting US cold chain approval following the successful relicensing from Allergan last year. To reiterate, RTD studies are ongoing.

Matt

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next